Cheaper medications await if you know where to look.   Read More

If you're not covered, this is what you need to do now.   Read More

After the closing bell Monday, Eli Lilly and Amylin Pharmaceuticals announced that they're going to hold a conference call for analysts and investors about their diabetes drug Byetta. Why?   Read More

As we head into my last free summer weekend before USC's football season kicks off, I wanted to clean out the Pharma's Market mailbox. (Actually I was looking for an apropos-of-nothing excuse to mention the Trojans.)    Read More

A cleverly titled research note always grabs my attention out of the dozens that clutter my inbox every morning. So, I couldn't pass up this one on Alnylam Pharmaceuticals with the sub-head, "Eighty Percent of Success is Showing Up --Woody Allen."   Read More

The market cap of Dow component Johnson & Johnson is a whopping $200 billion. Abbott Labs is valued at less than half that. But think of ABT as kind of a mini-me JNJ because like Johnson & Johnson, ABT has cobbled together a similar three-siloed business of drugs, devices and consumer products.    Read More

Flying isn't the only rip-off. Your whole vacation is littered with hidden fees and surcharges, but you don't have to pay them all.   Read More

Before I get to my favorite biotech saga, there are noteworthy, if not newsworthy, press releases out this morning from two takeout targets. Genentech put out a statement from the special independent board committee that's been appointed to handle the Roche buyout offer.   Read More

Worried about your bank failing? Here's how to make sure you are protected.   Read More

More than ten years after Pfizer brought Viagra to market and brought erectile dysfunction out of the closet a new survey says a lot of men are still too embarrassed to talk about impotence with their doctor.    Read More